SPA Trial - Prostate Stereotactic body radiation therapy with or without Androgen deprivation therapy, a phase III randomized controlled trial"

Project objectives

This is a multicenter randomized phase 3 study which therefore aims to evaluate the biochemical relapse-free survival (bRFS) defined as an increase in PSA above the NADIR (lower PSA value obtained after treatment) of 2ng/ml in patients with prostate cancer and undergoing stereotaxic treatment with or without hormonal therapy.

Start and end date

Project Manager

Coordinating institution of the project

Other Institutions involved

• IOV Padua
• Humanitas Rozzano, Milan
• Humanitas Gavazzeni, Bergamo
• Tor Vergata, Rome
• Bio-medical Campus, Rome
• Esine, Brescia